Measurement of Tissue Factor Activity in Whole Blood

Richard A. Santucci; Jonathan Erlich; Joanne Labriola; Mark Wilson; K. J. Kao; Thomas S. Kickler; Charles Spillert; Nigel Mackman

doi:10.1055/s-0037-1613835

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2000; 83(03): 445-454
DOI: 10.1055/s-0037-1613835

Review Article

Schattauer GmbH

Measurement of Tissue Factor Activity in Whole Blood

Authors

Richard A. Santucci

¹The Scripps Research Institute, La Jolla, CA
Jonathan Erlich

¹The Scripps Research Institute, La Jolla, CA
Joanne Labriola

¹The Scripps Research Institute, La Jolla, CA
Mark Wilson

²University Surgical Associates, Louisville, KY
K. J. Kao

³University of Florida, Gainesville, FL
Thomas S. Kickler

⁵The Johns Hopkins University, Baltimore, USA
Charles Spillert

⁴UMD New Jersey Medical School, Newark
Nigel Mackman

¹The Scripps Research Institute, La Jolla, CA

Abstract

Summary

High circulating levels of the procoagulant molecule tissue factor (TF) are associated with thrombosis in a variety of diseases including unstable angina, cancer, and sepsis. Currently, there are no clinical assays to measure the level of TF activity in whole blood. We present an assay called Tissue Factor Clotting Time (“TiFaCT^™”) that detects fibrin formation in human blood. The mean baseline clotting time in a healthy population was 472 ± 94 s (mean ± SD, n = 150). Bacterial lipopolysaccharide (LPS or endotoxin) shortened the clotting time in a time-dependent manner. Inhibitory anti-TF antibodies prolonged the clotting time of LPS-stimulated blood, indicating that the shortened clotting time was due to induction of TF expression. Patients with unstable angina had shortened mean baseline clotting time (284 ± 86, n = 13) compared with healthy volunteers (474 ± 98, n = 30), suggesting that these patients had elevated levels of circulating TF. The TiFaCT assay should prove clinically useful in quantifying the levels of circulating TF in patients at risk of thrombosis.

Key words

Tissue factor - whole blood - thrombosis

Full Text

References

References
1 Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
2 Bach RR. Initiation of coagulation by tissue factor. Crit Rev Biochem 1988; 23: 339-68.
3 Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol 1992; 29: 170-6.
4 Rickles RF, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 11: 237-48.
5 Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276-81.
6 Miller CL, Graziano C, Lim RC, Chin M. Generation of tissue factor by patient monocytes: correlation to thromboembolic complications. Thromb Haemost 1981; 46: 489-95.
7 Kappelmayer J, Berecki D, Misz M, Olah L, Fekete I, Csiba L, Blasko G. Monocytes express tissue factor in young patients with cerebral ischemia. Cerebrovasc Dis 1999; 08: 235-9.
8 Gando S, Nanzaki S, Sasaki S, Kemmotsu O. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998; 79: 1111-5.
9 Gando S, Kameue T, Nanzaki S, Hayakawa T, Nakanishi Y. Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome. Crit Care Med 1997; 25: 1820-6.
10 Østerud B, Flæstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: Related to an unfavorable prognosis. Thromb Haemost 1983; 49: 5-7.
11 Leatham E, Bath P, Tooze J, Camm A. Increased monocyte tissue factor expression in coronary disease. Br Heart J 1995; 73: 10-3.
12 Luther Th, Flössel C, Hietschhold V, Koslowski R, Muller M. Flow cytometric analysis of tissue factor (TF) expression on stimulated monocytes – comparison to procoagulant activity of mononuclear blood cells. Blut 1990; 61: 375-8.
13 Albrecht S, Kotzsch M, Siegert G, Luther T, Grossmann H, Grosser M, Müller M. Detection of circulating tissue factor and factor VII in a normal population. Thromb Haemost 1996; 75: 772-7.
14 Suefuji H, Ogawa H, Yasue H, Kaikita K, Soejima H, Motoyama T, Mizuno Y, Oshima S, Saito T, Tsuji I, Kumeda K, Kamikubo Y, Nakamura S. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134: 253-9.
15 Amirkhosravi A, Alexander M, May K, Francis DA, Warnes G, Bigerstaff J, Francis JL. The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay. Thromb Haemost 1996; 75: 87-95.
16 Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. Blood 1997; 89: 3270-6.
17 Hansen CB, van Deurs B, Petersen LC, Rao LV. Discordant expression of tissue factor and its activity in polarized epithelial cells. Asymmetry in anionic phospholipid availability as a possible explanation. Blood 1999; 94: 1657-64.
18 Iochmann S, Reverdiau-Moalic P, Beaujean S, Rideau E, Lebranchu Y, Bardos P, Gruel Y. Fast detection of tissue factor and tissue factor pathway inhibitor messenger RNA in endothelial cells and monocytes by sensitive reverse transcription-polymerase chain reaction. Thromb Res 1999; 94: 165-73.
19 Spillert CR, Lazaro EJ. Modified recalcification time (MRT): a sensitive cancer test? Review of the evidence. J Natl Med Assoc 1995; 87: 687-92.
20 Engstad CS, Lia K, Rekdal O, Olsen JO, Osterud B. A novel biological effect of platelet factor 4 (PF4): enhancement of LPS-induced tissue factor activity in monocytes. J Leukocyte Biol 1995; 58: 575-81.
21 Halvorsen H, Olsen JO, Osterud B. Granulocytes enhance LPS-induced tissue factor activity in monocytes via an interaction with platelets. J Leukoc Biol 1993; 54: 275-82.
22 Levy GA, Edgington TS. Lymphocyte cooperation is required for amplification of macrophage procoagulant activity. J Exp Med 1980; 151: 1232-44.
23 Østerud B. Tissue factor expression by monocytes: regulation and path. Blood Coagul Fibrinolysis 1998; (Suppl. 01) S9-S14.
24 Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer. J Lab Clin Med 1981; 98: 917-28.
25 Dvorak HF, DeWater LV, Bitzer AM, Dvorak AM, Anderson D, Harvey VS, Bach R, Davis GL, DeWolf W, Carvalho CA. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 1983; 43: 4334-42.
26 Giesen P, Rauch U, Bohrmann B, Kling D, Roque M, Fallon J, Badimon JJ, Riederer M, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
27 Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factordependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
28 Broze Jr. GJ, Girard TJ, Novotny WF. The lipoprotein-associated coagulation inhibitor. Prog Hemost Thromb 1991; 10: 243-68.
29 Østerud B, Bjorklid E. The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentrations of endotoxin. Scand J Haematol 1982; 29: 175-84.
30 Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-23.
31 Shollet-Martin S, Ollivier V, Amiral J, de Prost D. Binding of an anti D dimer monoclonal antibody to endotoxin-activated monocytes. Demonstration by immunogold-silver staining. Thromb Res 1988; 52: 1-9.
32 Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. Am Heart J 1979; 97: 155-8.
33 Chandler WL, Schmer G. Evaluation of a new dynamic viscometer for measuring the viscosity of whole blood and plasma. Clin Chem 1986; (32) 505-7.
34 Hett DA, Walker SN, Pilkington SN, Smith DC. Sonoclot analysis. Br J Anaesth 1995; 75: 771-6.
35 Morrissey JH, Fair DS, Edgington TS. Monoclonal antibody analysis of purified and cell-associated tissue factor. Thromb Res 1988; 52: 247-61.
36 Despotis GJ, Hogue Jr. CW, Santoro SA, Joist JH, Barnes PW, Lappas DG. Effect of heparin on whole blood activated partial thromboplastin time using a portable, whole blood coagulation monitor. Crit Care Med 1995; 23: 1674-9.
37 Gerotziafas GT, Bara L, Bloch MF, Makris PE, Samama MM. Treatment with LMWHs inhibits factor VIIa generation during in vitro coagulation of whole blood. Thromb Res 1996; 81: 491-6.
38 Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 1998; 82: 12P-8P.
39 Tipping PG, Erlich JH, Apostolopoulos J, Mackman N, Loskutoff DJ, Holdsworth SR. Glomerular tissue factor expression in crescentic glomerulonephritis. Correlations between antigen, activity, and mRNA. Am J Pathol 1995; 147: 1736-48.
40 Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989; 09: 2752-5.
41 Parry GCN, Mackman N. NF-κB-mediated transcription in human monocytic and endothelial cells. Trends Cardiovasc Med 1998; 08: 138-42.
42 Ernofsson M, Siegbahn A. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thromb Res 1996; 83: 307-20.
43 Østerud B. Cellular interactions in tissue factor expression by blood monocytes. Blood Coagul Fibrinolysis 1995; 06: S20-S5.
44 Rand MD, Lock JB, van’t Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-45.
45 Misumi K, Ogawa H, Yasue H, Soejima H, Suefuji H, Nishiyama K, Takazoe K, Kugiyama K, Tsuji I, Kumeda K, Nakamura S. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998; 81 (01) 22-6.
46 Agraou B, Corseaux D, McFadden EP, Bauters A, Cosson A, Jude B. Effects of coronary angioplasty on monocyte tissue factor response in patients with stable or unstable angina. Thromb Res 1997; 88 (02) 237-43.
47 Erlich JH, Fearns C, Mathison J, Ulevitch RJ, Mackman N. Lipopolysaccharide induction of tissue factor expression in rabbits. Infect Immun 1999; 67: 2540-6.
48 Johnson K, Hung D. Novel anticoagulants based on inhibition of the factor VIIa/tissue factor pathway. Coron Artery Dis 1999; 09: 83-7.
49 Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78: 471-7.
50 Arnljots B, Ezban M. Hedner Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. J Vasc Surg 1997; 25: 341-6.
51 Rebello SS, Blank HS, Rote WE, Vlasuk GPI, Lucchesi BR. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharmacol Exp Ther 1997; 283: 91-9.
52 Kelley RF, Refino CJ, Modi N, Sehl P, Lowe D, Pater C, Bunting S. A soluble tissue factor mutant is a selective anticoagulant and antithrobotic agent. Blood 1997; 89: 3219-27.
53 Kjalke M, Monroe DM, Hoffman M, Oliver JA, Ezban M, Roberts HR. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thromb Haemost 1998; 80: 578-84.